Cubist Systematic Strategies’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Cubist Systematic Strategies’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-914,286	Closed	-$810K	–	4779
2022 Q4	$810K	Buy	914,286 +74,542	+9%	+$98.9K	﹤0.01%	2641
2022 Q3	$1.32M	Buy	839,744 +10,665	+1%	+$24.2K	0.01%	2380
2022 Q2	$1.67M	Buy	829,079 +592,679	+251%	+$1.02M	0.01%	2022
2022 Q1	$551K	Buy	236,400 +220,209	+1,360%	+$687K	﹤0.01%	2479
2021 Q4	$75K	Buy	+16,191	New	+$101K	﹤0.01%	3255
2021 Q3	–	Sell	-21,028	Closed	-$204K	–	3272
2021 Q2	$204K	Buy	+21,028	New	+$167K	﹤0.01%	2555
2020 Q4	–	Sell	-28,335	Closed	-$316K	–	2771
2020 Q3	$316K	Sell	28,335 -296,265	-91%	-$2.71M	﹤0.01%	1968
2020 Q2	$2.04M	Buy	+324,600	New	+$1.24M	0.04%	782
2015 Q3	–	Sell	-10,430	Closed	-$184K	–	2066
2015 Q2	$184K	Sell	10,430 -7,190	-41%	-$92.4K	0.01%	1468
2015 Q1	$204K	Buy	+17,620	New	+$204K	0.01%	1521

Other funds holding SRNE

Paloma Partners Greenwich, Connecticut $1.36B AUM 249.29% 1-Year Est. Return

OCM

Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return

OFA

Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return

CGA

Crescent Grove Advisors Lake Forest, Illinois $1.2B AUM 23.08% 1-Year Est. Return

LCM

Lattice Capital Management Kirkland, Washington $49.5M AUM 28.58% 1-Year Est. Return

STB

S&T Bank Indiana, Pennsylvania $333M AUM 106.39% 1-Year Est. Return

GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return

HFRG

Houlihan Financial Resource Group Ashburn, Virginia $281M AUM 17.68% 1-Year Est. Return

VFA

Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return

GBWM

Granite Bay Wealth Management Portsmouth, New Hampshire $1.09B AUM 22.93% 1-Year Est. Return

Cubist Systematic Strategies's SRNE Position: Q1 2023 in Review

Cubist Systematic Strategies sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 914,286 shares — an estimated $810K sold.

Cubist Systematic Strategies first reported a position in SRNE in Q1 2015 and held it in 10 quarters. The position peaked at $2.04M in Q2 2020. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

Cubist Systematic Strategies reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
Cubist Systematic Strategies sold 914,286 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $810K.
Cubist Systematic Strategies first reported a position in Sorrento Therapeutics, Inc. in Q1 2015 and held it in 10 quarters.
Cubist Systematic Strategies's Sorrento Therapeutics, Inc. position peaked at $2.04M in Q2 2020.
34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on Cubist Systematic Strategies's 13F filing for Q1 2023, filed 15 May 2023.